Kalaris Therapeutics, Inc.
KLRSHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeKalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. The company carries a $86.4M market cap, placing it firmly in the micro-cap category. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Market Cap
$86.4M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-2.19
EPS (TTM)
$-1.88
EPS (Fwd)
$-1.66
ROE
-79.9%
ROA
-31.0%
Cash
$93.5M
Total Debt
$1.4M
Free CF
-$26.2M
52W Change
-14.3%
Annual Financials
Cash vs Debt
Where KLRS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, KLRS finished 33.79% below its 150-day moving average ($5.89) and 39.53% below its 200-day moving average ($6.45). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KLRS overbought or oversold?
At the September 3, 2026 close, KLRS's RSI(14) was 50.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Kalaris Therapeutics, Inc. holds $93.5M in cash against $1.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$26.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -79.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, KLRS has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Kalaris Therapeutics, Inc.'s trajectory.